6:02 PM
 | 
Jun 06, 2016
 |  BC Extra  |  Clinical News

Latest data show survival benefit for Ganymed's IMAB362

Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG (Mainz, Germany) plus chemotherapy led to longer overall survival (OS) and progression-free survival (PFS) than chemotherapy alone in the Phase II FAST study to treat gastric or gastroesophageal junction cancer. The company had already disclosed that the study met all its endpoints.

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >